Omeros (OMER) Prices $50M Upsized Share Offering at $13.10/Sh

Omeros Corporation (NASDAQ: OMER) announced today the pricing of its registered underwritten public offering of $50.0 million in shares of its common stock at a price to the public of $13.10 per share, before deducting underwriting discounts and other estimated offering expenses. The offering is expected to close on or about December 9, 2019, subject to the satisfaction of customary closing conditions. In addition, Omeros has granted the underwriter a 30-day option to purchase up to $7.5 million in shares of its common stock.

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.

Omeros intends to use the net proceeds of the offering for general corporate purposes, including funding clinical trials, pre-clinical studies, manufacturing, build-out of commercial infrastructure and other costs associated with advancing its development programs and product candidates toward regulatory submissions and potential commercialization. Omeros may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.

You May Also Be Interested In

• Cantor Fitzgerald Starts Nuvation Bio Inc (NUVB) at Overweight
• Entera Bio Ltd. (ENTX) files for 134.8M share offering by selling stockholders
• Curvature Securities terminates ATM sales pact with Planet Green